Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciencesFRA:82P 77 Debt-to-EBITDA is 3.48 as of Mar. 2026, which is 50% below its 10-year median of 6.98. GuruFocus rates FRA:82P with a GF Score™ of 77/100 and a GF Value™ of €26.49. The stock has 8 warning signs investors should review. Among 689 Drug Manufacturers companies, Pacira BioSciences ranks worse than 72.71% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Pacira BioSciences's Debt-to-EBITDA or its related term are showing as below:
FRA:82P'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.1 Med: 6.98 Max: 21.94
Current: 3.47
During the past 13 years, the highest Debt-to-EBITDA Ratio of Pacira BioSciences was 21.94. The lowest was -23.10. And the median was 6.98.
FRA:82P's Debt-to-EBITDA is ranked worse than 72.71% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs FRA:82P: 3.47
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pacira BioSciences Debt-to-EBITDA Related Terms
Pacira BioSciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ALVO, BIOA, COLL: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Pacira BioSciences (FRA:82P) has a Debt-to-EBITDA of 3.48 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pacira BioSciences. This is 50% below median its historical median of 6.98. According to the industry distribution chart, Pacira BioSciences ranks #501 out of 689 companies in the Drug Manufacturers industry, placing it in the top 72.7%.
Is Pacira BioSciences' Debt-to-EBITDA too high?
Pacira BioSciences' current Debt-to-EBITDA of 3.48 is 50% below median its 10-year median of 6.98. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Pacira BioSciences' value of 3.48 is 112.2% above this industry median. Based on the distribution chart, Pacira BioSciences ranks #501 out of 689 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Debt-to-EBITDA compare to ALVO and BIOA?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #501 out of 689 companies for Debt-to-EBITDA. This places Pacira BioSciences in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Pacira BioSciences' value of 3.48 is 112.2% above this benchmark. While the company's 10-year median is 6.98 vs. the industry median of 1.64, Pacira BioSciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Debt-to-EBITDA of 3.48 is 112.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pacira BioSciences. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Debt-to-EBITDA is 3.48, which is 50% below median its own 10-year median of 6.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Debt-to-EBITDA of 3.48. The stock's GF Value™ is €26.49, compared to a current price of €23.40 — trading 11.7% below its estimated fair value. The current Debt-to-EBITDA is 3.48, which is 50% below median its 10-year median of 6.98 and 112.2% above the Drug Manufacturers industry median of 1.64. Pacira BioSciences' overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Debt-to-EBITDA is 3.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €23.40 is trading 11.7% below its estimated GF Value™ of €26.49.
Key valuation signals for FRA:82P:
Debt-to-EBITDA: 3.48 (50% below median its 10-year median of 6.98)
GF Value™: €26.49 vs. price of €23.40 (11.7% below fair value)
Industry Position: 112.2% above the Drug Manufacturers median (#501 of 689)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
77GF Score
Get the complete analysis for FRA:82P
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
